Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.33 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.49 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.49 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.49 |
| ▸ | PLK4 | O00444 | 2/20 | 0.49 |
| ▸ | MARK3 | P27448 | 2/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.49 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.49 |
| ▸ | NQO2 | P16083 | 2/20 | 0.49 |
| ▸ | CDK9 | P50750 | 2/20 | 0.49 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.49 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.49 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.49 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.49 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL23795331 | 1.00 | ROCK1 (0.49) | ROCK1ROCK2PRKCDPKN2AURKB | |
| SCHEMBL30439326 | 0.98 | ROCK1 (0.51) | ROCK1ROCK2PRKCDPKN2AURKB | |
| SCHEMBL30439170 | 0.98 | ROCK1 (0.51) | ROCK1ROCK2PRKCDPKN2AURKB | |
| SCHEMBL23795344 | 0.98 | ROCK1 (0.51) | ROCK1ROCK2PRKCDPKN2AURKB | |
| SCHEMBL23795345 | 0.98 | ROCK1 (0.51) | ROCK1ROCK2PRKCDPKN2AURKB | |
| SCHEMBL23795305 | 0.87 | ROCK2 (0.47) | ROCK1ROCK2PRKCDPKN2AURKB | |
| SCHEMBL23795333 | 0.87 | ROCK2 (0.47) | ROCK1ROCK2PRKCDPKN2AURKB | |
| SCHEMBL23795409 | 0.85 | ROCK2 (0.68) | ROCK1ROCK2PRKCDPKN2AURKB | |
| SCHEMBL23795376 | 0.85 | ROCK2 (0.68) | ROCK1ROCK2PRKCDPKN2AURKB | |
| SCHEMBL30438995 | 0.85 | ROCK2 (0.68) | ROCK1ROCK2PRKCDPKN2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2025-04-01 | — | — | US | disclosed |
| CN-111116555-B | Rho kinase inhibitor and preparation method and application thereof | 北京盈科瑞创新药物研究有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3878846-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | Beijing Increase Innovative Drug Co., Ltd. (CN) | 2021-09-15 | — | — | EP | disclosed |
| CN-111116555-A | Rho kinase inhibitor and preparation method and application thereof | 北京盈科瑞创新药物研究有限公司 | 2020-05-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | ROCK1, RHOA, ROCK2 | ADRA2A 2898/4885ADRA2B 2229/4885OPRK1 2909/4885 |
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | ROCK1, RHOA, ROCK2 | ADRA2A 2898/4885ADRA2B 2229/4885OPRK1 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.